Does Amlodipine Increase Cancer Incidence?

To the Editor:

The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) amplifies the controversy over calcium antagonists and increased cancer risk. In this 36-month, placebo-controlled, randomized trial, the calcium antagonist amlodipine had no effect on the angiographic progression of coronary atherosclerosis or on the risk of major cardiovascular events. In the group assigned to amlodipine, the annualized rates of coronary artery bypass grafting and unstable angina were reduced by 1.0% and 2.1%, respectively.

Unfortunately, incident cancers increased in the group assigned to amlodipine. The annualized rate of incident cancers was 1.8% in the amlodipine group and 1.0% in the placebo group. Thus, the 0.8% annualized increase in incident cancer in the amlodipine group was similar in magnitude but opposite in direction to the 1.0% annualized reduction in coronary artery bypass surgery.

Because some observational data suggest that calcium antagonists may cause cancer, this finding in PREVENT warrants further investigation. From a public health perspective, for every 1 million patients taking amlodipine for 1 year, the incident cancer rate will increase by 8000 because of the drug. Perhaps we are trading one problem for another.

Mark R. Goldstein, MD, FACP
466 Crescent Drive
West Chester, PA 19382
mrgolds@aol.com

Response

We appreciate the comments of Dr Goldstein regarding the incidence of cancer seen with amlodipine in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Because of the concern raised by Pahor et al, we carefully reviewed each case of cancer with an independent group of oncologists. In view of the relatively small number of events, no firm conclusions could be reached regarding the risk of cancer associated with use of amlodipine. Additional cancer data, however, will be available in the next 2 to 3 years from several large-scale trials in which amlodipine is being compared with placebo or other antihypertensive strategies.

We believe that the reduction in the incidence of hospitalization for angina pectoris and the need for revascularization observed in PREVENT suggests a role for amlodipine in patients with coronary artery disease.

Bertram Pitt, MD
University of Michigan Medical Center
Robert P. Byington, PhD
Curt D. Furberg, MD, PhD
Michael E. Miller, PhD
Ward Riley, PhD
Wake Forest University School of Medicine

Donald B. Hunninghake, MD
University of Minnesota Hospital/Clinic

G.B. John Mancini, MD
University of British Columbia

Does Amlodipine Increase Cancer Incidence?
Mark R. Goldstein

_Circulation_. 2001;104:e5
doi: 10.1161/01.CIR.104.2.e5
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/104/2/e5

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/